MX2018001992A - Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. - Google Patents

Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.

Info

Publication number
MX2018001992A
MX2018001992A MX2018001992A MX2018001992A MX2018001992A MX 2018001992 A MX2018001992 A MX 2018001992A MX 2018001992 A MX2018001992 A MX 2018001992A MX 2018001992 A MX2018001992 A MX 2018001992A MX 2018001992 A MX2018001992 A MX 2018001992A
Authority
MX
Mexico
Prior art keywords
phosphoinositide
kinase inhibitors
heterocyclic compounds
tricyclic heterocyclic
compounds
Prior art date
Application number
MX2018001992A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Shuttleworth Stephen
Richard Liam Cecil Alexander
Alexandre Silva Franck
Elizabeth Gatland Alice
John Finnemore Daniel
Peter Alexander Rikki
Original Assignee
Karus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karus Therapeutics Ltd filed Critical Karus Therapeutics Ltd
Publication of MX2018001992A publication Critical patent/MX2018001992A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2018001992A 2015-08-19 2016-08-19 Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. MX2018001992A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1514754.9A GB201514754D0 (en) 2015-08-19 2015-08-19 Compounds
PCT/GB2016/052581 WO2017029521A1 (en) 2015-08-19 2016-08-19 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2018001992A true MX2018001992A (es) 2018-06-19

Family

ID=54258853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001992A MX2018001992A (es) 2015-08-19 2016-08-19 Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.

Country Status (9)

Country Link
US (1) US10442815B2 (enExample)
EP (1) EP3337807A1 (enExample)
JP (1) JP2018528942A (enExample)
CN (1) CN108349988B (enExample)
AU (1) AU2016307889A1 (enExample)
CA (1) CA2995909A1 (enExample)
GB (1) GB201514754D0 (enExample)
MX (1) MX2018001992A (enExample)
WO (1) WO2017029521A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597983A (en) 2009-08-20 2014-05-30 Karus Therapeutics Ltd Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
EP3668839B1 (en) 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
EP4069699A1 (en) 2019-12-05 2022-10-12 Verge Analytics, Inc. Fused tricyclic heterocyclic compounds as inhibitors of pikfyve kinase useful for the treatment of neurological diseases
CA3167339A1 (en) 2020-01-13 2021-07-22 Verge Analytics, Inc. Substituted pyrazolo-pyrimidines and uses thereof
WO2022169882A1 (en) 2021-02-03 2022-08-11 Verge Analytics, Inc. Methods and treatment of viral infection caused by sars-cov-2

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1922171B (zh) 2004-02-26 2012-10-17 Aska制药株式会社 嘧啶衍生物
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
ES2380795T3 (es) 2005-05-20 2012-05-18 Vertex Pharmaceuticals, Inc. Pirrolopiridinas útiles como inhibidores de proteínas quinasas
EP1979353A2 (en) 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
TW200801012A (en) 2006-04-26 2008-01-01 Piramed Ltd Phosphoinositide 3-kinase inhibitor compounds and methods of use
CA2650196A1 (en) 2006-04-26 2007-11-01 Stewart James Baker Pyrimidine derivatives as pi3k inhibitors
EP2035436B1 (en) * 2006-06-26 2011-05-25 UCB Pharma S.A. Fused thiazole derivatives as kinase inhibitors
EP2097422A4 (en) 2006-11-13 2010-04-14 Lilly Co Eli THIENOPYRIMIDINONE FOR THE TREATMENT OF INFLAMMATORY DISEASES AND CARCINOMAS
CA2677096A1 (en) 2007-01-31 2008-08-07 Vertex Pharmaceuticals Incorporated Kinase inhibitors
EP2139332A4 (en) 2007-03-28 2010-04-21 Merck Sharp & Dohme SUBSTITUTED PYRIDO [2,3-D] PYRIMIDIN DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
WO2010015520A1 (de) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituierte naphthyridine und ihre verwendung als arzneimittel
WO2010037765A2 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4-morpholino-pyrido[3,2-d]pyrimidines
GB2465405A (en) * 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
US8981087B2 (en) 2009-07-29 2015-03-17 Karus Therapeutics Limited Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
NZ597983A (en) * 2009-08-20 2014-05-30 Karus Therapeutics Ltd Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
EP3333161B1 (en) 2011-07-27 2020-02-19 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
BR112015011456A2 (pt) 2012-11-20 2017-07-11 Genentech Inc compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m
CN105358550B (zh) 2013-05-10 2018-04-06 卡鲁斯治疗有限公司 组蛋白脱乙酰基酶抑制剂
US20140377258A1 (en) 2013-05-30 2014-12-25 Infinity Pharmaceuticals, Inc. Treatment Of Cancers Using PI3 Kinase Isoform Modulators
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
JP6584391B2 (ja) 2013-10-10 2019-10-02 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
GB201321738D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321730D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use

Also Published As

Publication number Publication date
GB201514754D0 (en) 2015-09-30
US10442815B2 (en) 2019-10-15
CN108349988A (zh) 2018-07-31
CN108349988B (zh) 2021-10-01
CA2995909A1 (en) 2017-02-23
US20180244685A1 (en) 2018-08-30
AU2016307889A1 (en) 2018-03-08
JP2018528942A (ja) 2018-10-04
WO2017029521A1 (en) 2017-02-23
EP3337807A1 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
PH12017501817B1 (en) Heterocyclic compounds as lsd1 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
MY202022A (en) Pyrrolotriazine compounds as tam inhibitors
MD20160118A2 (ro) Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
MX2016013265A (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
MA39866A (fr) Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
MX377329B (es) Moduladores de ror gamma (ror?).
MX378111B (es) Moduladores de ror gamma (ror?).
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
SV2016005317A (es) Derivados de pirrolidina -2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1
MA39993A (fr) Dérivés de pyrrolidine -2,5-dione, compositions pharmaceutiques et procédés pour une utilisation en tant qu'inhibiteursde de ido1